Scaling Infusion Processes in Pharmaceutical Manufacturing: A Practical Guide

Executive Overview: Why scaling infusion processes is different from clinical infusion

Scaling infusion processes in pharmaceutical manufacturing presents unique challenges compared to clinical infusion. Manufacturing-scale operations require robust parameters, advanced equipment, and stringent controls suitable for volumes ranging from 10 L to 10,000 L, moving beyond the logic of hospital-based infusion.

The infusion therapy market is experiencing significant growth. Projections indicate a rise from USD 49.58 billion in 2024 to USD 83.10 billion by 2034, with a Compound Annual Growth Rate (CAGR) of 5.3%. Similarly, the global infusion pump market is expected to grow from USD 11.92 billion in 2024 to USD 21.13 billion by 2032, at a CAGR of 7.4%. Understanding these market dynamics is crucial for capacity planning and automation investments.

While guidance for hospital and clinic settings often omits scale-up specifics, this guide offers a practical, step-by-step framework for manufacturing. It incorporates real-world tips and considerations to navigate the complexities of large-scale infusion process development.

TH Tung (2022) notes that pump event logs and EHR data can be valuable for studying time discrepancies in infusion administration at scale.

Practical, Step-by-Step Scale-Up Framework

Step 1 — Define Scale-Up Targets and Success Criteria

Scale-up begins with a clear, shared vision of the growth trajectory—from bench to pilot to commercial scale—while preserving the core essence of the product. This section outlines the progression, critical endpoints that must remain equivalent, and the criteria that will guide decisions and handoffs during technology transfer.

Stage	Typical Scale	Batch Equivalence Endpoints
Bench scale	Approximately 5–10 L	API concentration, osmolarity, and sterility at target values
Pilot scale	Approximately 500–1,000 L	Maintain equivalence of API concentration, osmolarity, sterility with validated tolerances
Commercial scale	Approximately 5,000–20,000 L	Continue batch equivalence for API concentration, osmolarity, and sterility across production lots

Explicit and quantifiable acceptance criteria are essential for keeping the project on track across scales:

• Delivered dose accuracy within ±1–2% across scales.
• Time to deliver within ±3% of target across scales.
• Formulation stability within specified windows.

To ensure a robust transition, the scale-up plan must be documented with a clear linkage between design and control elements:

• Design of Experiments (DoE) factors influencing critical quality attributes (CQAs) and performance.
• Response metrics quantifying equivalence and performance across scales.
• Risk controls identifying potential deviations and remediation steps.
• Clear change-control linkage to ensure adjustments propagate through the transfer package.

Operational planning is reinforced by a concrete schedule and governance to support technology transfer:

• Allocate a 12-week window for pilot runs, with predefined go/no-go gates.
• scalable documentation to enable rapid handoffs and traceability.

Capacity justification and timing should align with market context. The 5.3% CAGR in infusion therapy informs the scale and pace of automation, equipment procurement, and line optimization to meet anticipated demand without compromising quality or reliability.

Gate	Timing (weeks)	Focus	Go/No-Go Criteria
Gate 1	Week 3	DoE planning complete; bench-to-pilot equivalence assessment	API concentration and osmolarity within spec; no sterility concerns; initial data trending toward stability windows
Gate 2	Week 6	Pilot runs conducted; initial risk controls validated	Delivered dose accuracy within ±1–2%; time-to-deliver within ±3%; preliminary stability data acceptable
Gate 3	Week 9	Pre-transfer readiness; documentation for scale-up and tech transfer	Process control strategy and CQAs established; change-control linkage confirmed; scalable documentation ready
Gate 4	Week 12	Final pilot data review; readiness for commercial scale transfer	All endpoints met across scales; full transfer package validated; automation and capacity plan justified

Bottom line: Define the journey in concrete terms—what success looks like at each stage, how it is measured, and how the plan remains connected to market needs. This creates a confident pathway from bench to scale, with clear accountability and a shared sense of momentum.

Step 2 — Map Process Parameters and Identify CPPs/CQAs for Scaling

Transitioning from lab to pilot to manufacturing involves understanding how process parameters behave differently at each scale. This step identifies critical process parameters (CPPs) and critical quality attributes (CQAs) that must be controlled during scaling and defines methods for translating setpoints across scales.

CPPs at Scale

• Target flow rate: Define a tight tolerance of ±1–2% to preserve dosing accuracy.
• Solution viscosity: Specify acceptable viscosity ranges and monitoring/adjustment methods.
• Temperature control: Maintain a strict temperature window with reliable feedback, documenting tolerable drift per scale.
• Bag/line hold times: Set maximum hold times at each scale to prevent degradation or sedimentation.
• Pump type suitability: Evaluate pump types (peristaltic vs. piston) based on wear, cleanability, response time, and formulation compatibility for each scale.

CQAs at Scale

• Delivered dose accuracy: Establish per-scale acceptance criteria.
• Sterility: Specify requirements and testing plans, including aseptic processing and closures.
• Particulate control: Set limits and outline inline filtration or monitoring strategies.
• pH stability: Define acceptable windows and maintenance methods.
• API integrity: Ensure API stability and identity preservation, defining testing cadence and limits.

Scale-Aware Transfer Function

Explain how pump setpoints translate into actual flow across scales, accounting for viscosity, temperature, and tubing characteristics. A scale-specific relationship, refined with calibration data, is key: Q_actual ≈ a_scale × Q_setpoint + drift_terms. Documenting a_scale and drift_terms along with expected uncertainty in Q_actual ensures data-driven decisions.

Scale-Specific Control Strategy

• Viscosity-driven drift: Implement inline viscosity measurement and adjust pump setpoints.
• Temperature-induced flow variation: Enforce tight temperature control and use feedback for pre-correction.
• Preventive adjustments: Monitor tubing wear, hold times, and calibration schedules to minimize drift.

Scale-to-Scale Transfer Model

Develop a living model mapping bench data to pilot and manufacturing, showing how CPPs and CQAs shift with scale. Use cross-scale data to update the transfer function and generate predictions for new scales. Keep documentation and dashboards updated for proactive issue identification.

Step 3 — Equipment Selection, Calibration, and System Integration

Hardware reliability is paramount. Select equipment that performs reliably across expected process variations and integrate it in an auditable, scalable, and compliant manner. Calibration should be systematic, not guesswork.

1. Pump selection and calibration cadence: Choose infusion pumps with validated accuracy across expected viscosities and pressures. Establish a clear calibration frequency (e.g., daily for critical lines, weekly for non-critical) and document the rationale. Maintain a standing calibration schedule for visibility.
2. Inline sensors with traceable certificates and documented calibration: Deploy inline flow meters, pressure sensors, and temperature sensors with traceable calibration certificates. Publish calibration intervals and store certificates in the Electronic Batch Record (EBR) for verifiable data traceability.
3. CIP/SIP-capable manifolds and sterile connectors; PAT-ready analytics: Utilize CIP (cleaning-in-place) and SIP (sterilization-in-place) capable components to minimize contamination risk and downtime. Ensure Process Analytical Technology (PAT) compatibility for integrated inline analytics.
4. Electronic batch records (EBR) and 21 CFR Part 11-compliant data logging: Implement an EBR that logs pump events, sensor outputs, and alarms with a clear audit trail. Ensure data logging meets 21 CFR Part 11 requirements for integrity and traceability (secure access, signed entries, tamper-evident records).
5. Measurement uncertainty budgets for each instrument: Document transparent uncertainty budgets to quantify confidence in readings. Update these budgets as new instruments or configurations are introduced. Use budgets to drive acceptance criteria, QA checks, and maintenance planning.

Step 4 — Design of Experiments (DoE) and Scale-Down/Up Mapping

DoE is the crucial translation layer that ensures lab insights are reliable at production scale. By deliberately varying factors like flow rate, viscosity, and temperature, you can uncover their interactions across scales and derive trustworthy large-scale predictions from small-batch data.

• DoE across scales: Use structured experiments to explore how flow rate, viscosity, and temperature interact from lab to production. Capture interactions and non-linearities to ensure lab data guides predictions for larger scales.
• Scale-down models for orthogonal validation: Develop scale-down representations that mimic large-scale hydrodynamics and residence time distribution. Use multiple validation angles to confirm that scale-down results accurately reflect full-scale behavior.
• Responses to monitor: Track delivered volume accuracy, time to deliver, API stability indicators, and sterility indicators to assess performance and identify early issues.
• Go/No-Go criteria based on CPP/CQA shifts: Set clear thresholds. If shifts exceed these, pause progression for deeper process understanding and potential rework.
• Data integration for cross-scale synchronization: Leverage pump logs and EHR-derived timing data to calibrate time-discrepancy corrections, improving cross-scale timing alignment and model fidelity.

Response	What it Measures	Data Sources	Go/No-Go Rule	Recommended Actions
Delivered volume accuracy	How close the actual delivered volume matches the target	Flow meters, pump logs	Deviation exceeds predefined limit	Recalibrate flow control, re-run DoE if needed
Time to deliver	Duration from start to finish of delivery	Instrument timers, pump logs	Timing variance beyond threshold	Investigate delays in pumping or mixing steps; adjust pacing or equipment
API stability indicators	Stability markers for API concentration and quality	Analytical assays, in-process tests	Stability drift or degradation beyond limits	Modify formulation or process parameters; re-run targeted DoE
Sterility indicators	Sterility test outcomes and indicators of microbial risk	Sterility assays, sensor alerts	Any sterility concern detected	Quarantine, investigate root cause, consider reprocessing or re-validation
CPP/CQA shifts	Changes in Critical Process Parameters and Critical Quality Attributes	Process sensors, quality measurements	Shifts exceed acceptable thresholds	Deeper process understanding, potential rework or redesign

In practice, this step integrates data from diverse sources. DoE acts as the compass guiding adjustments, while scale-down/up mapping serves as the map detailing how to stay on course from lab benches to full-scale systems.

Step 5 — Real-Time Monitoring, PAT, and Control Architecture

Real-time monitoring transforms data into actionable decisions during infusion. Inline PAT sensors (NIR, Raman, UV-Vis) track concentration, stability, and pH in flight, feeding signals to the control layer for a tighter feedback loop that maintains product specifications and reduces variability.

• Inline PAT methods: NIR, Raman, and UV-Vis sensors monitor concentration, stability, and pH during infusion, enabling immediate detection of drift and swift corrective actions.
• Time-synchronized data: Utilize pump event logs and EHR-derived timing data to study time discrepancies at scale, aligning dosing and event sequences across sites, machines, and shifts.
• Real-time control loops: Compensate for viscosity-driven flow drift and temperature fluctuations. Set robust alarm thresholds for safe interventions and continuity.
• Data integrity and security: Ensure tamper-evident logs, digital signatures, and secure multi-site data transmission to protect the chain of custody and auditability.
• Documentation and governance: Document system integration points, data flows, and cybersecurity measures as part of the manufacturing quality system.

In practice, Step 5 integrates measurement, control, and governance into a cohesive system. Live data, rapid decision-making, and rigorous security coexist to sustain quality, safety, and throughput.

Step 6 — Validation, Change Control, and Regulatory Readiness

Validation is an ongoing framework that scales from bench to full production, remaining aligned with current regulatory expectations. This blueprint ensures you stay ahead of evolving guidelines.

Scale	Typical Volume	Purpose	Predefined Acceptance Criteria
Bench	5 L	Nominal runs and process understanding	Stable key variables within design space; initial performance metrics met; reproducibility demonstrated
Pilot	500–1,000 L	Robustness and parameter sensitivity; near-plant conditions	Process robustness across runs; control strategy validated; variability bounded
Manufacturing	5,000–20,000 L	Full production readiness; scale-up confirmation	Validated performance; control strategy and CAPA plan in place; readiness for tech transfer

• Implement formal change-control processes: Conduct risk assessments (FMEA), secure cross-functional approvals, and maintain full traceability for all changes.
• Align with GMP and ICH guidelines for QbD and lifecycle management: Adopt Quality by Design (QbD) principles, establish a design space, and build a robust process understanding. Implement Process Analytical Technology (PAT) for real-time monitoring and data-driven decisions.
• Prepare technical transfer documentation: Ensure comprehensive documentation for site-to-site transfer, including master formula, process parameters, equipment lists, validation data, batch records, and a transfer plan.
• Develop a guiding principle: a dynamic, searchable knowledge base: Maintain a living repository of guidelines, standards, and regulatory expectations, tagged, versioned, and updated regularly. Ensure cross-functional ownership.
• Document regulatory context and refresh schedule: Record relevant regulatory context and establish a regular refresh cadence (e.g., quarterly or semi-annually) with assigned ownership and an audit-friendly log of updates.

Takeaway: Detailing multi-scale validation, enforcing rigorous change control, aligning with QbD and lifecycle management, and maintaining a living regulatory knowledge base create a resilient, audit-ready pathway for technology transfer.

Real-World Implementation: Case Studies and Practical Lessons

Case Study A — Scaling a sterile IV infusion formulation from 2 L to 1000 L

Scaling a sterile IV infusion from bench to pilot scale involves balancing concentration and osmolarity, controlling shear, and maintaining delivery time. This case study details key decisions and results from a 1:500 scale-up.

• Scale factor and formulation integrity: A 1:500 scale factor (2 L to 1000 L) maintained drug concentration and osmolarity within ±2%.
• CPP shifts and corrective actions: Pump accuracy and bag integrity shifts were resolved by recalibrating the pump and adjusting line lengths.
• DoE-informed process window: DoE results identified an optimal flow range to minimize shear and preserve emulsion stability.
• Performance across batches: Three consecutive pilot batches achieved time-to-delivery within ±13% of target.
• Lessons learned: Plan capital expenditure for capacity growth, reinforce sterilization and CIP/SIP processes, and leverage PAT for real-time quality assurance.

Case Study B — DoE-driven scale-up of a high-viscosity parenteral solution

High viscosity can impact timing and torque during batch production. This case demonstrates a deliberate DoE-driven approach, combined with real-time sensing and robust data capture, for a challenging formulation scale-up.

• Viscosity challenges: A piston pump with torque protection was adopted, complemented by gravimetric flow verification for reliable pumping and an independent check on flow accuracy.
• Delivery time sensitivity: Delivery time sensitivity to viscosity was mapped, and a control algorithm was implemented to modulate pump speed in real-time based on viscosity sensor readings, leading to faster, more predictable delivery.
• Temperature stabilization: Temperature stabilization expanded the formulation’s stability window, and pH stability was revalidated at each scale transition.
• Pilot data capture: Comprehensive pump logs and EBR traceability were collected to build an auditable data trail, enhancing regulatory readiness.

Key takeaway: Leveraging initial-scale DoE findings and validating with a scale-down model reduces risk in manufacturing-scale deployment, leading to faster, more confident production launches.

Measurement, Calibration, and Uncertainty in Infusion Scale-Up

Calibration and Traceability of Infusion Pumps and Analyzers

Calibration is fundamental to safe infusions and accurate measurements. Addressing drift prevents error accumulation and ensures patient safety. This guide clarifies device calibration for auditability and inspection readiness.

Line Type	Calibration Frequency	Traceability
Critical lines	Daily	Traceable to NIST or equivalent
Non-critical lines	Quarterly	Traceable to NIST or equivalent

Uncertainty budgets:

• Flow rate: ±1–2%
• Volumetric measurement: ±0.5–1%
• Timing: ±0.5–1.0%
• Temperature: ±0.2–0.5 °C

Any drift necessitates recalibration and re-runs. Calibration certificates must be accessible in the EBR for smooth audits and investigations.

Calibration methods to document

• Gravimetric verification
• Bubble point tests
• Flow verification against master standards

Inline Sensors, PAT, and Data Integrity

Inline sensors provide real-time data, transforming production lines into dynamic information feeds. They enable PAT by offering instant visibility into concentration and stability, supporting data integrity across the supply chain.

• Real-time concentration and stability monitoring: Inline sensors measure API presence and stability. Spectroscopy (NIR, Raman) provides rapid checks of API integrity during infusion, acting as a live quality screen.
• EHR data integration for timing alignment and cross-site harmonization: Linking process data with EHR or clinical metadata allows for synchronized timing analyses and harmonized data across sites, enabling faster comparisons and more reliable scaling decisions.
• Data governance, compliance, and secure data transmission: Enforce 21 CFR Part 11 compliant audit trails, robust access controls, and secure data transmission to maintain data trustworthiness and enable auditable collaboration.

Bottom line: Converging inline sensing, PAT, and careful data governance yields faster, safer insights that integrate seamlessly across sites and systems.

Regulatory and Quality Considerations

Trust and quality are essential for scaling innovations. Keeping regulatory and quality goals at the forefront ensures a smooth transition.

• Document formulation stability across all scales; maintain full traceability: Assess stability from lab to production with clear acceptance criteria. Track all components—raw materials, suppliers, batch numbers, test certificates, and change history.
• Track container closure systems: Monitor materials, lots, integrity results, and sterilization status for consistent performance.
• Validate sterility, particulates, and endotoxin controls: Use validated sterility methods with ongoing verification. Control particulates through validated filtration strategies. Monitor endotoxin levels as required. Conduct container closure integrity tests (CCIT/CCI) and document results.
• Adopt a lifecycle management approach with QbD, PAT, and continuous improvement: Define target product profile, establish design space, and build process understanding (QbD). Implement real-time monitoring and controls (PAT). Employ formal change control, risk management, ongoing training, audits, and alignment with evolving guidelines for continuous improvement.

By integrating these practices, teams can move swiftly without compromising safety, effectiveness, or compliance as guidelines evolve.

Watch the Official Trailer